Burning Rock Biotech (BNR) Cash & Current Investments (2019 - 2026)

Burning Rock Biotech (BNR) has reported Cash & Current Investments for 8 consecutive years, with $65.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 5.18% year-over-year to $65.2 million; the TTM figure through Mar 2026 stood at $65.2 million (down 5.18% YoY), while the FY2025 annual figure was $69.2 million, down 3.72% from the prior year.
• Cash & Current Investments came in at $65.2 million for Q1 2026 at Burning Rock Biotech, down from $67.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $200.9 million in Q1 2022, with the low at $63.2 million in Q2 2025.
• Average Cash & Current Investments over 5 years is $98.2 million, with a median of $79.3 million recorded in 2024.
• Across the five-year window, Cash & Current Investments tumbled 45.03% in 2022 and decreased 5.18% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $130.1 million in 2022, then tumbled by 34.32% to $85.4 million in 2023, then decreased by 14.92% to $72.7 million in 2024, then decreased by 6.69% to $67.8 million in 2025, then decreased by 3.91% to $65.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $65.2 million, $67.8 million, and $65.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.